Elevating Thoracic Oncology Through Shared Principles

Our team of accomplished scientists, clinicians, and healthcare professionals are committed to advance research excellence and drug development in Asia.

The unique local patient demographics of lung cancer has led many initial research efforts to be centered on a type of mutation known as Epidermal Growth Factor Receptors (EGFR), the disease has now become the “poster child” for precision oncology.

The term “Precision Oncology” is used to describe molecular profiling of a tumor and using diverse strategies in cancer medicine to treating cancer. Through rigorous study, innovative methodologies, and a relentless pursuit of knowledge, we strive to deepen our understanding of lung cancer through bio marker discoveries, trends monitoring and improve survival outcomes for lung cancer patients.

Collaboration transcends borders. ATORG actively seeks partnerships with Key Opinion Leaders in thoracic cancer research institutions, healthcare providers, industry partners and advocacy organizations across Asia and beyond.

Together, we can amplify our impact and accelerate progress in cancer treatment research.

We believe that knowledge is power. Through educational initiatives, outreach programs, advisory board meetings and events, we seek to reduce the stigma associated with lung cancer and empower clinicians and healthcare professionals with new drugs information they can consider in improving lung cancer treatment and research.

We understand that lung cancer affects not only patients but also their families and loved ones. That’s why our approach is deeply rooted in patient-centered care.

We are dedicated to provide personalized support, guidance, and the highest quality of care tailored to each individual’s unique needs.

ATORG is at the forefront of early detection initiatives for lung cancer. Our aim is to develop and enhance methods for detecting the disease in its earliest, most treatable stages, giving patients the best chance for a healthier future.

Advocacy is a driving force behind our work. We actively advocate for increased awareness, research funding, and policy changes that will benefit lung cancer patients and their families, both in Asia and across the globe.

Our team of accomplished scientists, clinicians, and healthcare professionals are committed to advance research excellence and drug development in Asia. The unique local patient demographics of lung cancer has led many initial research efforts to be centered on a type of mutation known as Epidermal Growth Factor Receptors (EGFR), the disease has now become the “poster child” for precision oncology.

The term “Precision Oncology” is used to describe molecular profiling of a tumor and using diverse strategies in cancer medicine to treating cancer. Through rigorous study, innovative methodologies, and a relentless pursuit of knowledge, we strive to deepen our understanding of lung cancer through bio marker discoveries, trends monitoring and improve survival outcomes for lung cancer patients.

Collaboration transcends borders. ATORG actively seeks partnerships with Key Opinion Leaders in thoracic cancer research institutions, healthcare providers, industry partners and advocacy organizations across Asia and beyond. Together, we can amplify our impact and accelerate progress in cancer treatment research.